Manufacturer or GPO Program year 2024 Source: CMS Open Payments

Biofrontera Bioscience GmbH

Germany

CMS manufacturer 100001181887

Open in the dashboard

General payments

$7,099

32 payments

Research payments

$4,032,273

254 payments

Ownership & investment interest

$0

None reported

Through program year 2024, Biofrontera Bioscience GmbH reported paying $7,099 in general payments and $4,032,273 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2024 Research $1,342,985 150
2023 General $448 6
2023 Research $1,972,716 72
2022 General $6,651 26
2022 Research $716,572 32

Breakdown

Top recipients General payments · program year 2023
  1. Vivian Laquer Dermatology · Irvine, CA $229 2 payments
  2. Nathalie Zeitouni Dermatology · Phoenix, AZ $196 2 payments
  3. Edward Lain Dermatology · Austin, TX $23 2 payments
Top research recipients Research payments · program year 2024
  1. Delricht Research $245,384 15 payments
  2. Austin Institute For Clinical Research $237,800 22 payments
  3. Skin Search of Rochester, Inc. $161,852 10 payments
  4. Dartmouth Clinical Trials Office $115,058 15 payments
  5. Dermatology/Cosmetic Laser Medical Associates of La Jolla, Inc. $108,054 7 payments
  6. Integrity Clinical Research at Dermatology $92,630 5 payments
  7. Forcare Clinical Research $55,646 4 payments
  8. Alliance dermatology & MOHS Center P.C. $51,154 5 payments
  9. AboutSkin Research, LLC $47,834 5 payments
  10. Derm Research $36,755 17 payments
Products the payments named General payments · program year 2023
  1. Ameluz Dermatology $448 50% · 3 recipients
  2. BF-RhodoLED Dermatology $229 26% · 1 recipient
  3. BF-RhodoLED XL Dermatology $219 24% · 2 recipients

Each share is of this company’s general payments naming a product in 2023. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2023
  1. Dermatology $448 100% · 3 practitioners

Each share is of this company’s general payments to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. California $229 51% · 1 recipient
  2. Arizona $196 44% · 1 recipient
  3. Texas $23 5% · 1 recipient

Each share is of this company’s general payments in 2023 where a state was reported.

What the payments were for General payments · program years 2022–2024
  1. Travel and Lodging $3,860 9 payments
  2. Food and Beverage $3,114 15 payments
  3. Gift $77 7 payments
  4. Entertainment $48 1 payment
Companies with a similar name General payments · program years 2022–2024
  1. Biofrontera Inc. MA, United States $1,389,315

Grouped by name only. CMS publishes no corporate ownership, so a shared name does not mean a shared parent.

32 general · 254 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record